The effect of statin use on lens density as assessed by pentacam hr® lens densitometry in adults

Year 2016, Volume: 3 Issue: 6, 245 - 9, 15.06.2016

Akin Cakir , Alptug Tokatli Taner Kar Yildiray Yildirim Eyup Duzgun Emrah Erdal

https://doi.org/10.17546/msd.34944

Abstract

Objective: To investigate the association between statin use and cataract development by using Pentacam HR Scheimpflug camera system.

Material and Methods: Total 208 age and sex matched participants were included in this prospective, case-control study. 104 long-term statin users as study group and 104 non-statin users as control group constituted to the study. Lens densitometry measurements were performed with the Pentacam HR® (Oculus, Wetzlar, Germany) from three areas (anterior, nuclear, and posterior). These measurements were compared between the groups.

 Results: There were no significant difference at the basic clinical variables (p=0.121, p=0.778). The mean duration of statin use of the study group was 5,4±4,3 years. The mean value of lens densitometry measurement at nuclear area tended to be lower in statin users than controls, but difference was not statistically significant (9.20±1.00 vs 9.35±1.20; p:0.346). However, the mean lens densitometry values at the anterior and posterior areas of statin users were found to be significantly higher than controls (10.44±1.32 vs 9.16±1.09;p<0.001; 7.86±0.49 vs 7.63±0.38; p<0.001,respectively).

Conclusion: The current study finds that long-term statin use seems to be associated with an increased risk of cortical cataracts (anterior-posterior) but not incidence of nuclear cataracts.

Keywords

Statin, Cataract; Pentacam HR®

The effect of statin use on lens density as assessed by pentacam hr® lens densitometry in adults

Abstract

References

• World Health Organization Office of Information. Blindness and Visual Disability: Part II: Major Causes Worldwide. WHO fact sheet no 143. Geneva: WHO; 1997.
• Leuschen J, Mortensen EM, Frei CR, et al. Association of statin use with cataracts: a propensity score-matched analysis. JAMA Ophthalmol. 2013;131(11):1427-34.
• Davignon J, Laaksonen R. Low-density lipoprotein-independent effects of statins. Curr Opin Lipidol 1999;10(6):543–559.
• Lai CL, Shau WY, Chang CH, et al. Statin use and cataract surgery: a nationwide retrospective cohort study in elderly ethnic Chinese patients. Drug Saf. 2013;36(10):1017-24.
• Klein BEK, Klein R, Lee KE, et al. Statin use and incident nuclear cataract. JAMA 2006;295(23):2752–2758.
• Tan JSL, Mitchell P, Rochtchina E, et al. Statin use and the long term risk of incident cataract: The Blue Mountains Eye Study. Am J Ophthalmol 2007;143(4):687–689.
• Chodick G, Heymann AD, Flash S, et al. Persistence with statins and incident cataract: A population-based historical cohort study. Ann Epidemiol 2010;20(2):136–142.
• Fong DS, Poon KYT. Recent Statin Use and Cataract Surgery. Am J Ophthalmol 2012;153:222–228.
• Schmidt J, Schmitt C, Hockwin O. No lens changes caused by simvastatin results from a prospective drug safety study. Lens Eye Toxic Res 1990;7:643–50.
• Harris ML, Bron AJ, Brown NA, et al. Absence of effect of simvastatin on the progression of lens opacities in a randomised placebo controlled study. Oxford Cholesterol Study Group. Br J Ophthalmol 1995;79:996–1002.
• Qian W, Soderberg PG, Chen E, et al. 3 year simvastatin treatment and lens nuclear back scattering. Br J Ophthalmol 2000;84:512–16.
• Smeeth L, Hubbard R, Fletcher A.E. Cataract and the use of statins: a case-control study. Q J Med 2003;96:337–343.
• Manchan CM, Hrynchak PK, Irvin EL. Age-related cataract is associated with type 2 diabetes and statin use. Optom Vis Sci. 2012;89:1165-1171.
• Wise SJ, Nathoo NA, Etminan M, et al. Statin use and risk for cataract: a nested case-control study of 2 populations in Canada and United States. Can J Cardiol. 2014;30:1613-1619.
• Klein BE, Cruickshanks KJ, Klein R. Leisure time,sunlight exposure and cataracts. Doc Ophthalmol.1995;88:295-305.
• Cumming RG, Mitchell P, Leeder SR. Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med. 1997;337:8-14.
• Grosser N, Hemmerle A, Berndt G, et al. The antioxidant defense protein heme oxygenase 1 is a novel target for statins in endothelial cells. Free Radic Biol Med. 2004;37:2064-2071.
• Stoll LL, McCormick ML, Denning GM, et al. Antioxidant effects of statins. Drugs Today. 2004;40:975-990.
• Klein BE, Klein R, Lee KE, et al. Markers of inflammation, vascular endothelial dysfunction, and age-related cataract. Am J Ophthalmol. 2006;141:116-122.
• Leung BP, Sattar N, Crilly A, et al. A novel antiinflammatory role for simvastatin in inflammatory arthritis. J Immunol. 2003;170:1524-1530.
• Albert MA, Danielson E, Rifai N, et al. Effect of statin therapy on C-reactive protein levels: the Pravastatin Inflammation/CRP Evaluation (PRINCE): a randomized trial and cohort study. JAMA. 2001;286:64-70.
• Gerson RJ, MacDonald JS, Alberts AW, et al. On the etiology of subcapsular lenticular opacities produced in dogs receiving HMG-CoA reductase inhibitors. Exp Eye Res. 1990;50:65-78.
• Cenedella RJ. Cholesterol and cataracts. Surv Ophthalmol. 1996;40(4):320-337.
• Mori M, Li G, Abe I, et al. Lanosterol synthase mutations cause cholesterol deficiency-associated cataracts in the Shumiya cataract rat. J Clin Invest. 2006;116(2):395-404.
• Zhao L, Chen XJ, Zhu J, et al. Lanosterol reverses protein aggregation in cataracts. Published online 22 July 2015. doi:10.1038/nature14650.
• Xu K, Hao Y. Mol Med Rep. Determination of the density of human nuclear cataract lenses. Mol Med Rep. 2013 Nov;8(5):1300-1304